September 12, 2017European Heart Journal200 citationsOpen Access
View Full Paper2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Structured PICO
P
Population
Patients with atherosclerotic cardiovascular disease or familial hypercholesterolaemia
I
Intervention
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
This document provides the 2017 update of the ESC/EAS Task Force practical clinical guidance for PCSK9 inhibition in patients with ASCVD or familial hypercholesterolemia.
Abstract
A correction has been published: European Heart Journal, Volume 39, Issue 22, 7 June 2018, Pages 2105